...
首页> 外文期刊>Liver international : >Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis
【24h】

Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis

机译:丙型肝炎病毒相关肝硬化患者直接作用抗病毒治疗过程中的凝血评估

获取原文
获取原文并翻译 | 示例

摘要

Abstract Background & Aims The effect of direct‐acting‐antivirals ( DAA ) on coagulation of hepatitis‐C‐virus ( HCV )‐related cirrhosis is unknown. Methods We investigated 28 patients on DAA treatment and performed prothrombin‐time, thrombin generation with and without thrombomodulin, whole‐blood thromboelastometry, as well as the individual procoagulants ( II , VIII , XIII , von Willebrand) and anticoagulants, antithrombin and protein‐C. Results Patients had undetectable HCV ‐ RNA at the end‐of‐ treatment and at 12‐weeks after end‐of‐treatment (sustained virological response). Transaminases were significantly decreased at both end‐of‐treatment and at 12‐weeks. Prothrombin‐time declined at 12‐weeks, but did not reach statistical significance. Factor‐ II , protein‐C and antithrombin increased significantly at end‐of‐treatment ( P .001) and persisted at 12‐weeks. Factor‐ VIII decreased at end‐of‐treatment and to a greater extent at 12‐weeks when reached statistical significance ( P .05). Factor‐ VIII /protein‐C ratio decreased sharply, reached statistical significance at end‐of‐treatment ( P .01) and persisted at 12‐weeks. Von‐Willebrand decreased at end‐of‐treatment and reached statistical significance at 12‐weeks ( P .001). Endogenous‐thrombin‐potential without thrombomodulin increased significantly at end‐of‐treatment ( P .01) and persisted at 12‐weeks. No changes were observed after addition of thrombomodulin. Endogenous‐thrombin‐potential ratio (with/without thrombomodulin) decreased and reached statistical significance at 12‐weeks ( P .05). Thromboelastometry clotting time decreased sharply, reached statistical significance at end‐of treatment ( P .001) and persisted at 12‐weeks. Conclusions Treatment with DAA s in HCV ‐related cirrhosis results in improvement of the individual pro‐ and anticoagulants. It can be hypothesised that the net effect does not substantially modify their balance (as shown by the unchanged thrombin generation in the presence of thrombomodulin) but makes it more stable and less amenable to be perturbed as presumably occurs before treatment when there is a partial deficiency for both.
机译:抽象背景&amp;目的是直接作用 - 抗病毒(DAA)对乙型肝炎病毒(HCV)的凝固的影响 - 相关性肝硬化是未知的。方法研究DAA治疗患者28名患者,进行凝血酶蛋白 - 时间,凝血酶蛋白生成,血小板发作,血液调节蛋白,全血血栓发球菌,以及个体促凝血剂(II,VIII,XIII,von Willebrand)和抗凝血剂,抗凝血酶和蛋白-c 。结果患者在治疗结束时具有未检测的HCV - RNA,治疗结束后12周(持续的病毒学反应)。在治疗结束和12周内,转氨酶显着降低。凝血酶原时间在12周内下降,但没有达到统计学意义。因子II,蛋白-c和抗抗凝血蛋白在治疗结束时显着增加(P& .001),并在12周持续存在。因子 - viii在达到统计学意义时在12周的治疗结束时减少,并且在12周的情况下(P <.05)。因子 - VIII /蛋白-C比率急剧下降,治疗结束时达到统计学意义(P <.01),并在12周持续存在。 von-willebrand在治疗结束时降低,12周达到统计学意义(P& .001)。在治疗结束(P <0.01)时,没有血栓调节蛋白的内源性凝血酶电位显着增加(P <.01),并在12周持续存在。在加入血栓调节蛋白后没有观察到变化。内源 - 凝血酶 - 电位比(带/不带血栓调节蛋白)降低并在12周下达到统计学显着性(P <.05)。血管紧节动力测定凝血时间急剧下降,在治疗结束时达到统计学意义(P <.001),并持续在12周。结论DAA S在HCV -Relelated肝硬化中的治疗导致各种促凝血剂的改善。可以假设净效应不会显着改变它们的平衡(如存在血栓调节蛋白存在的不变凝血酶产生),但是在存在部分缺陷之前可能发生更稳定并且更易于扰乱。对彼此而言。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号